Advertisement

Drugs

, Volume 78, Issue 14, pp 1481–1488 | Cite as

Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma

  • Yvette N. Lamb
Adis Drug Evaluation
  • 238 Downloads

Abstract

Intravenous elotuzumab (Empliciti™), a monoclonal antibody targeting the signalling lymphocytic activation molecule F7 (SLAMF7) glycoprotein, is approved for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in previously-treated adult patients. In the pivotal, multinational, phase III ELOQUENT-2 trial in adults with relapsed and/or refractory multiple myeloma, elotuzumab in combination with lenalidomide and dexamethasone significantly prolonged median progression-free survival (PFS) and increased overall response rate (ORR; co-primary endpoints) compared with lenalidomide and dexamethasone alone. The clinical benefit of elotuzumab was maintained over the longer term (≤ 4 years’ minimum follow-up); final overall survival data are awaited. Health-related quality of life was not negatively impacted by the addition of elotuzumab. Elotuzumab combination therapy had a generally manageable tolerability profile and the most common adverse events (AEs) of grade ≥ 3 severity were haematological (e.g. lymphocytopenia, anaemia, thrombocytopenia, neutropenia). Elotuzumab plus lenalidomide and dexamethasone extends the treatment options available for the management of relapsed and/or refractory multiple myeloma.

Notes

Acknowledgements

During the peer review process, the manufacturer of elotuzumab was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

Yvette Lamb is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

References

  1. 1.
    Naymagon L, Abdul-Hay M. Novel agents in the treatment of multiple myeloma: a review about the future. J Hematol Oncol. 2016;9:52.CrossRefGoogle Scholar
  2. 2.
    Lonial S, Durie B, Palumbo A, et al. Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives. Leukemia. 2016;30:526–35.CrossRefGoogle Scholar
  3. 3.
    Tai YT, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112:1329–37.CrossRefGoogle Scholar
  4. 4.
    Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14(9):2775–85.CrossRefGoogle Scholar
  5. 5.
    Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621–31.CrossRefGoogle Scholar
  6. 6.
    Bristol-Myers Squibb Pharma EEIG. Empliciti: summary of product characteristics. 2017. http://www.ema.europa.eu/. Accessed 9 Aug 2018.
  7. 7.
    Bristol-Myers Squibb Company. Empliciti™ (elotuzumab) for injection, for intravenous use: US prescribing information. 2017. http://packageinserts.bms.com/. Accessed 9 Aug 2018.
  8. 8.
    Bristol-Myers Squibb. Humanized anti-human SLAMF 7 monoclonal antibody. Empliciti® for IV infusion: Japanese prescribing information. 2016. http://www.pmda.go.jp/. Accessed 9 Aug 2018.
  9. 9.
    Collins SM, Bakan CE, Swartzel GD, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother. 2013;62(12):1841–9.CrossRefGoogle Scholar
  10. 10.
    Kurdi AT, Glavey SV, Bezman NA, et al. Antibody-dependent cellular phagocytosis by macrophages is a novel mechanism of action of elotuzumab. Mol Cancer Ther. 2018;17(7):1454–63.CrossRefGoogle Scholar
  11. 11.
    Rice AG, Dillon MBC, Van Abbema AM, et al. HuLuc63 in combination regimens with conventional and targeted therapies has additive and synergistic anti-tumour activity in pre-clinical models of myeloma. Blood. 2007;110(11):2517.Google Scholar
  12. 12.
    Balasa B, Yun R, Belmar NA, et al. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-alpha pathways. Cancer Immunol Immunother. 2015;64(1):61–73.CrossRefGoogle Scholar
  13. 13.
    Van Rhee F, Szmania SM, Dillon M, et al. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther. 2009;8(9):2616–24.CrossRefGoogle Scholar
  14. 14.
    Dimopoulos MA, Lonial S, White D, et al. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol. 2017;178(6):896–905.CrossRefGoogle Scholar
  15. 15.
    Richardson PG, Jagannath S, Moreau P, et al. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. Lancet Haematol. 2015;2(12):e516–27.CrossRefGoogle Scholar
  16. 16.
    Gibiansky L, Passey C, Roy A, et al. Model-based pharmacokinetic analysis of elotuzumab in patients with relapsed/refractory multiple myeloma. J Pharmacokinet Pharmacodyn. 2016;43(3):243–57.CrossRefGoogle Scholar
  17. 17.
    Passey C, Mora J, Dodge R, et al. An integrated assessment of the effects of immunogenicity on the pharmacokinetics, safety, and efficacy of elotuzumab. AAPS J. 2017;19(2):557–67.CrossRefGoogle Scholar
  18. 18.
    European Medicines Agency. Empliciti: CHMP assessment report. 2016. http://www.ema.europa.eu/. Accessed 9 Aug 2018.
  19. 19.
    Berdeja J, Jagannath S, Zonder J, et al. Pharmacokinetics and safety of elotuzumab combined with lenalidomide and dexamethasone in patients with multiple myeloma and various levels of renal impairment: results of a phase Ib study. Clin Lymphoma Myeloma Leuk. 2016;16(3):129–38.CrossRefGoogle Scholar
  20. 20.
    Dimopoulos MA, Lonial S, Betts KA, et al. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer. 2018.  https://doi.org/10.1002/cncr.31680.CrossRefPubMedGoogle Scholar
  21. 21.
    Suzuki K, Sunami K, Ohashi K, et al. Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis. Blood Cancer J. 2017;7(3):e540.CrossRefGoogle Scholar
  22. 22.
    Cella D, McKendrick J, Kudlac A, et al. Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study. Ann Hematol. 2018.  https://doi.org/10.1007/s00277-018-3469-4.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: multiple myeloma (version 4.2018). 2018. http://www.nccn.org/. Accessed 9 Aug 2018.
  24. 24.
    Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;24(Suppl 6):vi133–7.Google Scholar
  25. 25.
    Ailawadhi S, DerSarkissian M, Duh MS, et al. Cost offsets in the treatment journeys of patients with relapsed/refractory multiple myeloma (RRMM) [abstract no. 5599]. Blood. 2017;130(Suppl 1):5599.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations